Alpha Pro Tech
Alpha Pro Tech's revenue rose 2.2% to $59 million in fiscal 2025. Its operating margin was 6.5%, up from 6.0% a year earlier. Free cash flow was $2 million, down 8.5%. It paid out $3 million in dividends and buybacks, 193% of free cash flow. The diluted share count fell 6.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Alpha Pro Tech does
Alpha Pro Tech makes two kinds of products. The first is building supplies that keep weather out of houses: housewrap, the sheet that goes under a home's siding, along with tape and flashing for windows and doors, and synthetic underlayment that goes under roof shingles. The second is single-use protective clothing, such as shoe covers, caps, gowns, coveralls and lab coats, plus face masks and face shields. Its customers are building supply and roofing distributors, and clean rooms, drug and electronics factories, labs, hospitals and dental offices, almost all in the United States.
In 2025 the company had total sales of $59,142,000, and building supplies, the larger segment, brought in $36,031,000 of it. It sells mostly through independent distributors, under its own brand and under other companies' labels. It names DuPont, Berry Global, Owens Corning and GAF as its main rivals in building supplies, and Kimberly-Clark, 3M and others in protective clothing.
The company's offices are in Aurora, Ontario, Canada. It makes building products in Valdosta, Georgia, and masks and other gear in Nogales, Arizona. Much of its protective clothing and some building products come from Harmony, a joint venture in India in which it owns 41.66%, and from contract makers in Asia and Mexico. In March 2026 it had 122 full-time employees.
Its biggest risks, as it describes them
- Its reliance on a joint venture in India and on contract makers in Asia and Mexico, which brings currency, supply and partner risks.
- Losing a large customer, or a large customer ordering less, could cut its sales.
- Tariffs and other countries' responses could raise its costs and disrupt its supply chain.
- Strong competition from much larger companies in both building supplies and protective clothing.
- Its growth depends on bringing new products to market and having customers accept them.
Income statement
From fiscal 2016 to 2025, earnings per share grew 6.3% a year and net income 1.0% a year, as buybacks cut the share count by 37%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 16 | 16 | 20 | 19 | 17 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 19.9x | 21.9x | 20.7x | 16.2x | 12.9x |
| Quick ratio | 10.5x | 11.7x | 12.8x | 8.9x | 7.1x |
Cash flow
Projections
Project Alpha Pro Tech's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Alpha Pro Tech shares on the open market, and 5 insiders sold $417,209.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Charles D MontgomeryDirector | Sold | 21,943 | $5.04 | $110,593 | Form 4 |
| Sep 28, 2026 | Donna MillarDirector, 10% owner | Sold | 6,971 | $5.04 | $35,134 | Form 4 |
| May 15, 2026 | David R GarciaDirector | Sold | 6,186 | $5.56 | $34,394 | Form 4 |
| May 14, 2026 | David R GarciaDirector | Sold | 4,900 | $5.88 | $28,812 | Form 4 |
| May 12, 2026 | Charles D MontgomeryDirector | Sold | 20,000 | $6.25 | $125,000 | Form 4 |
| May 11, 2026 | Charles D MontgomeryDirector | Sold | 3,886 | $7.03 | $27,319 | Form 4 |
| Mar 17, 2026 | John RitotaDirector | Sold | 2,260 | $4.94 | $11,164 | Form 4 |
| Mar 16, 2026 | John RitotaDirector | Sold | 4,740 | $4.84 | $22,942 | Form 4 |
| Dec 5, 2025 | James BuchanDirector | Sold | 4,740 | $4.61 | $21,851 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 11.3% | −2.3% | 5.2% |
| Altman Z'' | 16.41 | 12.31 | 12.40 |
| Accruals ratio | −6.4% | −2.5% | 1.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Alpha Pro Tech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alpha Pro Tech | FY25 | 2.2% | 6.5% | 2.9% | — | — | — | |
| ImmuCell | FY25 | 4.3% | 6.0% | 4.4% | — | 1.2x | — | Compare |
| RxSight | FY25 | −3.9% | −35.8% | −14.4% | −82.9% | — | 3 | Compare |
| Organogenesis | FY25 | 17.0% | 7.9% | −4.3% | — | — | — | Compare |
| Insight Molecular Diagnostics | FY25 | 115.6% | −1,260.8% | −625.6% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 46 | 44 | 47 | 47 | 103 | 69 | 62 | 61 | 58 | 59 |
| Revenue growth | 2.7% | −4.7% | 5.9% | 0.1% | 120.1% | −33.2% | −9.7% | −1.2% | −5.5% | 2.2% |
| Gross profit | 17 | 18 | 18 | 17 | 50 | 25 | 22 | 23 | 23 | 22 |
| Research and development | 0 | 0 | — | — | — | — | — | — | — | — |
| Operating income | 4 | 3 | 4 | 3 | 32 | 8 | 5 | 4 | 3 | 4 |
| Net income | 3 | 3 | 4 | 3 | 27 | 7 | 3 | 4 | 4 | 4 |
| Diluted EPS (US$) | 0.19 | 0.18 | 0.26 | 0.23 | 1.92 | 0.50 | 0.26 | 0.35 | 0.35 | 0.33 |
| Diluted shares (millions) | 17 | 15 | 14 | 13 | 14 | 14 | 13 | 12 | 11 | 11 |
| Cash flow | ||||||||||
| Cash from operations | 7 | 4 | 2 | 3 | 18 | −0 | 4 | 8 | 6 | 2 |
| Capital expenditure | 0 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 4 | 1 |
| Free cash flow | 7 | 3 | 1 | 2 | 17 | −3 | 4 | 8 | 2 | 2 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 7 | 4 | 4 | 2 | 3 | 4 | 4 | 4 | 4 | 3 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 10 | 9 | 7 | 6 | 23 | 16 | 16 | 20 | 19 | 17 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 36 | 34 | 34 | 38 | 69 | 67 | 65 | 69 | 74 | 74 |
| Total liabilities | 3 | 3 | 2 | 5 | 9 | 5 | 4 | 7 | 12 | 12 |
| Shareholders' equity | 33 | 31 | 32 | 33 | 59 | 62 | 61 | 62 | 62 | 62 |
| Margins and ratios | ||||||||||
| Gross margin | 36.8% | 39.6% | 38.0% | 36.4% | 49.1% | 36.9% | 35.0% | 37.3% | 39.6% | 38.1% |
| Operating margin | 8.0% | 6.7% | 8.3% | 6.5% | 30.8% | 11.6% | 7.5% | 6.8% | 6.0% | 6.5% |
| Net margin | 6.9% | 6.0% | 7.8% | 6.4% | 26.2% | 9.8% | 5.3% | 6.8% | 6.8% | 6.0% |
| Free cash flow margin | 14.2% | 6.3% | 3.0% | 3.9% | 16.7% | −4.4% | 6.1% | 12.5% | 3.3% | 2.9% |
| Rule of 40 (growth + FCF margin) | 16.9% | 1.7% | 8.9% | 4.0% | 136.8% | −37.5% | −3.6% | 11.3% | −2.3% | 5.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 9.2% | 8.2% | 11.4% | 9.2% | 58.6% | 11.2% | 5.4% | 6.8% | 6.3% | 5.7% |
| Return on assets | 8.4% | 7.5% | 10.6% | 8.3% | 50.4% | 10.0% | 5.0% | 6.3% | 5.5% | 4.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |